drug_type
RELEVANT_DRUG
intervention_type
Biologic (monoclonal antibody)
drug_description
Cetuximab (C225) is a chimeric IgG1 anti-EGFR monoclonal antibody that blocks ligand binding and EGFR activation/dimerization, promotes receptor internalization, inhibits downstream RAS–RAF–MEK–ERK and PI3K–AKT signaling, and mediates antibody-dependent cellular cytotoxicity (ADCC).
nci_thesaurus_concept_id
C1723
nci_thesaurus_preferred_term
Cetuximab
nci_thesaurus_definition
A recombinant, chimeric monoclonal antibody directed against the epidermal growth factor (EGFR) with antineoplastic activity. Cetuximab binds to the extracellular domain of the EGFR, thereby preventing the activation and subsequent dimerization of the receptor; the decrease in receptor activation and dimerization may result in an inhibition in signal transduction and anti-proliferative effects. This agent may inhibit EGFR-dependent primary tumor growth and metastasis. EGFR is overexpressed on the cell surfaces of various solid tumors.
drug_mesh_term
Cetuximab
drug_category
INHIBITORY ANTIBODY
drug_class
Inhibitor
drug_delivery_route
Intravenous
drug_mechanism_of_action
Chimeric IgG1 monoclonal antibody against EGFR that binds the extracellular domain to block ligand binding and receptor activation/dimerization, promotes receptor internalization, inhibits downstream RAS–RAF–MEK–ERK and PI3K–AKT signaling, and mediates Fc-dependent ADCC against EGFR-expressing tumor cells (most effective in RAS wild-type disease).
drug_name
Cetuximab
nct_id_drug_ref
NCT06440902